Skip to main content Accessibility help

Secular Trends of Hospitalization With Vancomycin-Resistant Enterococcus Infection in the United States, 2000–2006

  • Andrew M. Ramsey (a1) and Marya D. Zilberberg (a1) (a2)


Although the incidence of hospitalizations with infection due to vancomycin-resistant pathogens in the United States remained stable during 2000–2003, it increased from 4.60 to 9.48 hospitalizations per 100,000 population during 2003–2006. Hospitalizations with infection due to vancomycin-resistant pathogens also increased as a proportion of all US hospitalizations, from 3.16 to 6.51 hospitalizations with VRE infection per 10,000 total hospitalizations during 2003–2006. The number of hospitalizations with infection due to vancomycin-resistant pathogens is increasing in the United States. Because infection due to vancomycin-resistant organisms is associated with poor outcomes, the epidemiology of this trend needs further exploration.


Corresponding author

EviMedResearch Group, PO Box 303, Goshen, MA 01032 (


Hide All
1.Safdar, N, Maki, DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002;136:834844.
2.Kuehnert, MJ, Hill, HA, Kupronis, BA, Tokars, JI, Solomon, SL, Jernigan, DB. Methicillin-resistant Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis 2005;11:868872.
3.McDonald, LC, Owings, M, Jernigan, DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerglnfect Dis 2006;12:409415.
4.Zilberberg, MD, Shorr, AF, Kollef, MH. Secular trends in candidemia hospitalizations in the US, 2000–2005. Infect Control Hosp Epidemiol 2008;29:978980.
5.Zilberberg, MD, Shorr, AF, Kollef, MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008;14:929931.
6.Rafferty, ME, McCormick, MI, Bopp, LH, et al.Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cyto-toxin assay. Infect Control Hosp Epidemiol 1997;18:342344.
7.HCUPnet. Healthcare Cost and Utilization Project (HCUP). 2000-2004. Agency for Healthcare Research and Quality, Rockville, MD. Available at: Accessed May 24, 2008.
8.Sievert, DM, Rudrik, JT, Patel, JB, et al.Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46:668674.
9.Cannelli, Y, Eliopoulis, G, Mozaffari, E, Samore, M. Health and economie outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162:22232228.
10.Ofher-Agostini, M, Johnston, BL, Simor, AE, et al.Vancomycin-resistant enterococci in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2005. Infect Control Hosp Epidemiol 2008;29:271274.


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed